The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Self-citationIntravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
Schmidt-Erfurth, U., Kaiser, P. K., Korobelnik, J.-F., Brown, D. M., Chong, V., Nguyen, Q. D., Ho, A. C., Ogura, Y., Simader, C., Jaffe, G. J., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.011 · Cited by 822 · cited 8×
“Despite the frequent recurrence of fluid in a proportion of patients, the VA outcomes in the VIEW trials were similar between 2 mg aflibercept Q4wks/Q8wks and ranibizumab Q4wks.3,5 Whether the specific subgroup with pronounced fluid fluctuations is affected by less visual gain needs to be addressed in further studies.”
BackgroundMethodResultInfluentialSelf-citationA paradigm shift in imaging biomarkers in neovascular age-related macular degeneration
Schmidt-Erfurth, U., & Waldstein, S. M. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.07.007 · Cited by 390 · cited 1×
“There has been increased scientific interest in the correlation between retinal structure and visual function in nAMD.(9) Intraretinal fluid has been associated with worse VA in eyes that were treatment-naïve before undergoing treatment with ranibizumab, bevacizumab, or verteporfin.”
BackgroundSelf-citationJaffe, G. J., Martin, D. F., Toth, C. A., Daniel, E., Maguire, M. G., Ying, G.-S., Grunwald, J. E., & Huang, J. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.01.073 · Cited by 294
Self-citation
Cited by
Artificial intelligence and deep learning in ophthalmology
Ting, D. S. W., Pasquale, L. R., Peng, L., Campbell, J. P., Lee, A. Y., Raman, R., Tan, G. S. W., Schmetterer, L., Keane, P. A., & Wong, T. Y. (2019) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-313173 · Cited by 1,554
Artificial Intelligence and Deep Learning in Ophthalmology
Wang, Z., Keane, P. A., Chiang, M., Cheung, C. Y., Wong, T. Y., & Ting, D. S. W. (2022) · Artificial Intelligence in Medicine · doi:10.1007/978-3-030-64573-1_200 · Cited by 1,524
Age-related macular degeneration
Mitchell, P., Liew, G., Gopinath, B., & Wong, T. Y. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31550-2 · Cited by 1,511
Self-citationFully Automated Detection and Quantification of Macular Fluid in OCT Using Deep Learning
Schlegl, T., Waldstein, S. M., Bogunovic, H., Endstraßer, F., Sadeghipour, A., Philip, A.-M., Podkowinski, D., Gerendas, B. S., Langs, G., & Schmidt-Erfurth, U. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.10.031 · Cited by 597
Self-citationRETOUCH: The Retinal OCT Fluid Detection and Segmentation Benchmark and Challenge
Bogunovic, H., Venhuizen, F., Klimscha, S., Apostolopoulos, S., Bab-Hadiashar, A., Bagci, U., Beg, M. F., Bekalo, L., Chen, Q., Ciller, C., et al. (2019) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2019.2901398 · Cited by 273
Self-citation
Metadata
- Authors
- Waldstein, S. M., Simader, C., Staurenghi, G., Chong, N. V., Mitchell, P., Jaffe, G. J., Lu, C., Katz, T. A., & Schmidt-Erfurth, U.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 123
- Issue
- 7
- Pages
- 1521-1529
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W2346873848
- Cited by
- 172
- References
- 6
- FWCI
- 11.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials. https://app.cochat.ai/papers/10.1016/j.ophtha.2016.03.037
- The paper
- Waldstein, S. M., Simader, C., Staurenghi, G., Chong, N. V., Mitchell, P., Jaffe, G. J., Lu, C., Katz, T. A., & Schmidt-Erfurth, U. (2016). Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials. Ophthalmology. https://doi.org/10.1016/j.ophtha.2016.03.037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.